Healthcare
UroGen Pharma Ltd.(URGN)
Live Price
Offline$33.57
+2.32% today
1Y Change
+134.76%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $1.12B
- Revenue Growth
- +21.4%
- EPS Growth
- -7.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
UroGen Pharma Ltd. (URGN) is a Healthcare stock with a market cap of $1.12B and listed on NASDAQ. The stock last traded around $33.57 and up 134.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +21.4%, EPS growth of -7.8%, a dividend yield of 0.0%. What stands out right now is revenue +21.4%, EPS -7.8%, free cash flow -67.7% with operating margin -113.7% and ROIC -81.1%. Valuation already assumes a fairly strong business story at price/sales 10.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines URGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+21.4% vs +7.6% peer median
Operating Margin
Below sector median
-113.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +21.4% and EPS is at -7.8%, with operating margin around -113.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -4.9% | -8.8% | -10.1% |
2026 Mar 2, 2026 | -4.3% | -1.1% | +4.7% | -10.6% |
2025 Nov 6, 2025 | +4.2% | -1.3% | +1.6% | -2.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
URGN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
URGN Max Drawdown
-42.22%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for URGN and SPY.
Company Overview
UroGen Pharma Ltd.
NASDAQ Global Market
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
- Leadership
- Elizabeth A. Barrett
- IPO Date
- May 4, 2017
- Employees
- 234
- Street Address
- 400 Alexander Park
- Mailing
- Princeton, NJ, 08540
- Region
- Princeton, NJ, US
- Reporting Currency
- USD
- Investor Line
- 646 768 9780
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 10.2
- Price/Book
- โ
Growth
- Revenue
- +21.4%
- EPS
- -7.8%
- Free Cash Flow
- -67.7%
Profitability
- Gross Margin
- 88.7%
- Operating Margin
- -113.7%
- Net Margin
- -139.8%
- ROE
- 170.2%
- ROIC
- -81.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 4.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.